Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;145(6):843-846.
doi: 10.1007/s00401-023-02567-z. Epub 2023 Apr 5.

Clinical applicability of miR517a detection in liquid biopsies of ETMR patients

Sibylle Madlener  1 , Julia Furtner  2   3 , Natalia Stepien  4 , Daniel Senfter  4 , Lisa Mayr  4 , Maximilian Zeyda  4 , Leon Gramss  4 , Barbara Aistleitner  5 , Sabine Spiegl-Kreinecker  6 , Elisa Rivelles  7 , Christian Dorfer  8 , Karl Rössler  8 , Thomas Czech  8 , Amedeo A Azizi  4 , Andreas Peyrl  4 , Daniela Lötsch-Gojo  8 , Leonhard Müllauer  9 , Christine Haberler  10 , Irene Slavc  4 , Johannes Gojo  11
Affiliations

Clinical applicability of miR517a detection in liquid biopsies of ETMR patients

Sibylle Madlener et al. Acta Neuropathol. 2023 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Blood-derived miR517a is a specific biomarker for ETMR. a Graphical abstract of the study (created with BioRender). b tSNE clustering of NanoString miRNA data. c Heatmap of NanoString analysis of more than 800 miRNAs expressed in different brain tumors. d MiR517a expression in pediatric brain tumor tissues (NanoString data). e miR517a expression in ETMR tissues and controls measured by qRT-PCR. f miR517a expression in blood samples of ETMR patients. g CNV and miR517a expression detected in different analytes. h Receiver operating characteristic (ROC) of miR517a CNV in CSF samples. i ROC curve of miR517a expression in CSF samples. j ROC curve of miR517a in blood samples. NanoString analysis was performed with nSolver software 3.0 from NanoString. t SNE was calculated with r Studio. All qPCR experiments were performed in triplicates. Asterisks indicate significance (students t test; *P < 0.05, **P < 0.01, ***P < 0.001 analyzed with GraphPad Prism), and error bars indicate that mean ± S.D. ROC curves were analyzed in IBM SPSS statistics 27 and mapped with GraphPad Prism
Fig. 2
Fig. 2
Liquid biopsy detection of miRNA enables therapy monitoring in ETMR patients. a–c Different ETMR cases and matched MRI images (FLAIR, upper panel) as well as longitudinal monitoring of miR517a expression in serum for case#5 and plasma for case#7 and case#9 correlated to tumor volumes (lower panel). CNV of miR517a detected in tumor DNA and cfDNA from CSF for case#5 and case#9. d Swimmer plot of 5 ETMR patients, including all dates of surgery, liquid biopsies, and MRIs. e Illustration of experimental workflow (created with BioRender). All qPCR experiments were performed in triplicates. Asterisks indicate significance (Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001), and error bars indicate mean ± S.D. GTR, gross total resection; NED, no evidence of disease
See this image and copyright information in PMC

References

    1. Chen S-H, Ho C-S, Chiu N-C, Chen H-J, Lin Y-J. Rare Brain Tumor in a Neonate. J Med Ultrasound. 2017;25:240–243. doi: 10.1016/j.jmu.2017.09.004. - DOI - PMC - PubMed
    1. Gojo J, Kjaersgaard M, Zezschwitz BV, Capper D, Tietze A, Kool M, Haberler C, Pizer B, Hoff KV. Rare embryonal and sarcomatous central nervous system tumours State-of-the art and future directions. Eur J Med Genet. 2022;66:104660. doi: 10.1016/j.ejmg.2022.104660. - DOI - PubMed
    1. von Hoff K, Haberler C, Schmitt-Hoffner F, Schepke E, de Rojas T, Jacobs S, Zapotocky M, Sumerauer D, Perek-Polnik M, Dufour C, van Vuurden D, Slavc I, Gojo J, Pickles JC, Gerber NU, Massimino M, Gil-da-Costa MJ, Garami M, Kumirova E, Sehested A, Scheie D, Cruz O, Moreno L, Cho J, Zeller B, Bovenschen N, Grotzer M, Alderete D, Snuderl M, Zheludkova O, Golanov A, Okonechnikov K, Mynarek M, Juhnke BO, Rutkowski S, Schüller U, Pizer B, von Zezschwitz B, Kwiecien R, Wechsung M, Konietschke F, Hwang EI, Sturm D, Pfister SM, von Deimling A, Rushing EJ, Ryzhova M, Hauser P, Łastowska M, Wesseling P, Giangaspero F, Hawkins C, Figarella-Branger D, Eberhart C, Burger P, Gessi M, Korshunov A, Jacques TS, Capper D, Pietsch T, Kool M. Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro Oncol. 2021 doi: 10.1093/neuonc/noab136. - DOI - PMC - PubMed
    1. Hwang EI, Kool M, Burger PC, Capper D, Chavez L, Brabetz S, Williams-Hughes C, Billups C, Heier L, Jaju A, Michalski J, Li Y, Leary S, Zhou T, von Deimling A, Jones DTW, Fouladi M, Pollack IF, Gajjar A, Packer RJ, Pfister SM, Olson JM. Extensive molecular and clinical heterogeneity in patients with histologically diagnosed CNS-PNET treated as a single entity: A report from the children’s oncology group randomized ACNS0332 trial. J Clin Oncol. 2018;36:3388–3395. doi: 10.1200/JCO.2017.76.4720. - DOI - PMC - PubMed
    1. Khan S, Solano-Paez P, Suwal T, Lu M, Al-Karmi S, Ho B, Mumal I, Shago M, Hoffman LM, Dodgshun A, Nobusawa S, Tabori U, Bartels U, Ziegler DS, Hansford JR, Ramaswamy V, Hawkins C, Dufour C, André N, Bouffet E, Huang A, Gonzalez CVA, Stephens D, Leary S, Marrano P, Fonseca A, Thacker N, Li BK, Lindsay HB, Lassaletta A, Bendel AE, Moertel C, Morales La Madrid A, Santa-Maria V, Lavarino C, Rivas E, Perreault S, Ellezam B, Weil AG, Jabado N, Oviedo A, Yalon-Oren M, Amariglio L, Toledano H, Dvir R, Loukides J, Van Meter TE, Nakamura H, Wong T-T, Wu K-S, Cheng C-J, Ra Y-S, La Spina M, Massimi L, Buccoliero AM, Reddy A, Li R, Gillespie GY, Adamek D, Fangusaro J, Scharnhorst D, Torkildson J, Johnston D, Michaud J, LafayCousin L, Chan J, Van Landeghem F, Wilson B, Camelo-Piragua S, Kabbara N, Boutarbouch M, Hanson D, Jacobsen C, Wright K, Vibhakar R, Levy JM, Wang Y, Catchpoole D, Gerber N, Grotzer MA, Shen V, Plant A, Dunham C, Gil J, da Costa M, Ramanujachar R, Raabe E, Rubens J, Phillips J, Gupta N, Demir HA, Dahl C, Jorgensen M, Hwang EI, Packer RJ, Smith A, Tan E, Low S, Lu J-Q, Ng H-K, Kresak JL, Gururangan S, Pomeroy SL, Sirachainan N, Hongeng S, Magimairajan V, Sinha R, Mushtaq N, Antony R, Sato M, Samuel D, Zapotocky M, Afzal S, Walter A, Tihan T, Tsang DS, Gajjar A, Wood P, Cain JE, Downie PA, Gottardo N, Branson H, Laughlin S, Ertl-Wagner B, Kulkarni AV, Taylor MD, Drake J, Ibrahim GM, Dirks PB, Rutka JT, Somers GR, Hazrati L-N, Bourdeaut F, Padovani L, Grundy RG, Mazewski CM, Fouladi M. Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. Lancet Child Adolesc Heal. 2021;5:800–813. doi: 10.1016/S2352-4642(21)00245-5. - DOI - PubMed

Publication types

MeSH terms